Q3 2024 13F Holders as of 30 Sep 2024
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
77.1M
-
Number of holders
-
169
-
Total 13F shares, excl. options
-
67.6M
-
Shares change
-
+2.2M
-
Total reported value, excl. options
-
$1.52B
-
Value change
-
+$52.6M
-
Put/Call ratio
-
0.69
-
Number of buys
-
91
-
Number of sells
-
-86
-
Price
-
$22.47
Significant Holders of Nurix Therapeutics, Inc. - Common Stock, par value $0.001 per share (NRIX) as of Q3 2024
203 filings reported holding NRIX - Nurix Therapeutics, Inc. - Common Stock, par value $0.001 per share as of Q3 2024.
Nurix Therapeutics, Inc. - Common Stock, par value $0.001 per share (NRIX) has 169 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 67.6M shares
of 77.1M outstanding shares and own 87.57% of the company stock.
Largest 10 shareholders include BlackRock, Inc. (7.18M shares), Redmile Group, LLC (4.28M shares), VANGUARD GROUP INC (4.01M shares), BAKER BROS. ADVISORS LP (3.88M shares), Deep Track Capital, LP (3.87M shares), WELLINGTON MANAGEMENT GROUP LLP (3.48M shares), PRICE T ROWE ASSOCIATES INC /MD/ (3.07M shares), T. Rowe Price Investment Management, Inc. (2.55M shares), STATE STREET CORP (2.37M shares), and ARK Investment Management LLC (2.22M shares).
This table shows the top 169 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.